| Recruiting | Study to Evaluate Pharmacokinetics, Relative Bioavailability, Palatability of Obefazimod Minitablet Formulatio Healthy | Phase 1 | 2026-03-03 |
| Recruiting | Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease Moderately to Severely Active Crohn Disease | Phase 2 | 2024-10-30 |
| Active Not Recruiting | ABTECT - Maintenance Ulcerative Colitis | Phase 3 | 2023-01-16 |
| Completed | ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 Ulcerative Colitis | Phase 3 | 2022-12-21 |
| Completed | ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 Ulcerative Colitis | Phase 3 | 2022-10-10 |
| Withdrawn | Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease Patients Crohn Disease | Phase 2 / Phase 3 | 2022-09-19 |
| Active Not Recruiting | Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis Ulcerative Colitis | Phase 2 | 2021-12-03 |
| Completed | Safety and Pharmacokinetics Study in Healthy Japanese Volunteers Healthy Volunteers | Phase 1 | 2021-09-27 |
| Completed | Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464 Healthy | Phase 1 | 2020-12-17 |
| Terminated | ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19 COVID-19 | Phase 2 / Phase 3 | 2020-07-01 |
| Completed | Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Coli Ulcerative Colitis | Phase 2 | 2020-01-13 |
| Completed | Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Ar Rheumatoid Arthritis | Phase 2 | 2019-10-25 |
| Recruiting | ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma Carcinoma, Hepatocellular | Phase 1 / Phase 2 | 2019-08-30 |
| Completed | Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis Ulcerative Colitis | Phase 2 | 2019-08-13 |
| Completed | Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis Rheumatoid Arthritis | Phase 2 | 2019-07-04 |
| Completed | Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis Ulcerative Colitis | Phase 2 | 2018-01-20 |
| Completed | ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis Ulcerative Colitis | Phase 2 | 2017-11-16 |
| Completed | A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults HIV Infections, Health Volunteers | Phase 1 / Phase 2 | 2017-03-27 |
| Completed | ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment HIV Infection | Phase 2 | 2016-05-01 |
| Completed | Safety, PK and PD Study of ABX464 in Untreated HIV Patients Human Immunodeficiency Virus Infections | Phase 2 | 2015-01-01 |
| Completed | Clinical Efficacy of ABX203 Therapeutic Vaccine in HBeAg Negative Patients With Chronic Hepatitis B Chronic Hepatitis B | Phase 2 / Phase 3 | 2014-12-01 |
| Completed | Food Effect on Pharmacokinetic Parameters of ABX464 Healthy Volunteers | Phase 1 | 2014-09-01 |
| Completed | ABX464 First in Man Study Healthy Volunteers | Phase 1 | 2014-03-01 |